HomeAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
$28.06
Makalipas ang Oras ng Trabaho:(0.14%)+0.040
$28.10
Sarado: Set 12, 6:33:26 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$28.68
Sakop ng araw
$27.91 - $28.86
Sakop ng taon
$20.39 - $53.96
Market cap
1.30B USD
Average na Volume
568.27K
P/E ratio
10.51
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 174.41M | -4.38% |
Gastos sa pagpapatakbo | 44.31M | 10.91% |
Net na kita | 31.03M | -18.23% |
Net profit margin | 17.79 | -14.51% |
Kita sa bawat share | 0.85 | -9.57% |
EBITDA | 56.80M | -16.92% |
Aktuwal na % ng binabayarang buwis | 21.11% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 231.75M | 6.42% |
Kabuuang asset | 1.62B | 8.30% |
Kabuuang sagutin | 857.85M | 10.24% |
Kabuuang equity | 757.48M | — |
Natitirang share | 46.50M | — |
Presyo para makapag-book | 1.76 | — |
Return on assets | 6.51% | — |
Return on capital | 7.49% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 31.03M | -18.23% |
Cash mula sa mga operasyon | 35.59M | -48.50% |
Cash mula sa pag-invest | -625.00K | 99.11% |
Cash mula sa financing | -30.20M | -181.84% |
Net change in cash | 4.91M | 142.56% |
Malayang cash flow | 12.67M | 117.69% |
Tungkol
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Itinatag
1996
Headquarters
Website
Mga Empleyado
2,028
